Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.natcopharma.co.in | |
Market Cap | 17,910.99 Cr. | |
Enterprise Value(EV) | 17,331.78 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 71.34 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 14.02 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.01 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 307.42 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 3.25 | Calculated using Price: 1,000.00 |
Dividend Yield | 0.55 | Period Ending 2023-03 |
No. of Shares Subscribed | 17.91 Cr. | 179,109,870 Shares |
FaceValue | 2 | |
About Natco Pharma Ltd. | ||
Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). It is also engaged in contract manufacturing business, whereby it undertake selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. It has diversified into the business of crop health sciences to leverage is skills in organic chemistry. |
1 Day |
|
+0.32% |
1 Week |
|
+4.65% |
1 Month |
|
+5.30% |
3 Month |
|
+20.73% |
6 Month |
|
+18.19% |
1 Year |
|
+76.46% |
2 Year |
|
+26.23% |
5 Year |
|
+85.36% |
10 Year |
|
+599.08% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 15.9 | 14.41 | 33.21 | 29.7 | 19.75 | 12.71 | 11.27 | 4.06 | 15.66 | |
Return on Capital Employed (%) | 14.89 | 17.49 | 39.21 | 35.28 | 23.71 | 14.82 | 13.99 | 4.86 | 18.06 | |
Return on Assets (%) | 9.69 | 9.58 | 23.43 | 23.05 | 16.02 | 10.3 | 9.43 | 3.43 | 13.29 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 846 | 1,296 | 1,649 | 3,072 | 3,489 | 3,774 | 4,122 | 4,264 | 4,874 | 5,294 | |
Non Curr. Liab. | 119 | 28 | 38 | 47 | 83 | 118 | 143 | 135 | 101 | 67 | |
Curr. Liab. | 414 | 493 | 627 | 592 | 729 | 685 | 526 | 710 | 683 | 878 | |
Minority Int. | 5 | 5 | 4 | 4 | 2 | 11 | 2 | ||||
Equity & Liab. | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,239 | |
Non Curr. Assets | 901 | 985 | 1,230 | 1,584 | 1,956 | 2,262 | 2,447 | 2,622 | 2,657 | 2,889 | |
Curr. Assets | 483 | 837 | 1,087 | 2,131 | 2,347 | 2,326 | 2,345 | 2,487 | 3,000 | 3,350 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 1,384 | 1,822 | 2,318 | 3,715 | 4,303 | 4,588 | 4,792 | 5,109 | 5,657 | 6,239 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 825 | 1,042 | 2,020 | 2,185 | 2,095 | 1,915 | 2,052 | 1,945 | 2,707 | 3,828 | |
Other Income | 15 | 10 | 14 | 40 | 130 | 107 | 106 | 99 | 129 | 115 | |
Total Income | 840 | 1,052 | 2,034 | 2,225 | 2,225 | 2,022 | 2,158 | 2,044 | 2,836 | 3,944 | |
Total Expenditure | -620 | -777 | -1,337 | -1,256 | -1,300 | -1,332 | -1,448 | -1,681 | -1,795 | -2,235 | |
PBIDT | 221 | 275 | 697 | 969 | 925 | 690 | 710 | 363 | 1,040 | 1,708 | |
Interest | -32 | -23 | -19 | -15 | -19 | -22 | -13 | -18 | -15 | -16 | |
Depreciation | -47 | -51 | -54 | -66 | -81 | -100 | -117 | -143 | -164 | -172 | |
Taxation | -2 | -48 | -140 | -192 | -182 | -111 | -137 | -32 | -147 | -243 | |
Exceptional Items | -15 | ||||||||||
PAT | 125 | 154 | 485 | 695 | 642 | 458 | 442 | 170 | 715 | 1,278 | |
Minority Interest | 4 | 1 | 1 | 1 | 2 | 3 | -2 | ||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 135 | 157 | 486 | 696 | 644 | 461 | 441 | 170 | 715 | 1,278 | |
Adjusted EPS | 8 | 9 | 28 | 38 | 35 | 25 | 24 | 9 | 39 | 71 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 144 | 93 | 112 | 346 | 464 | 669 | 417 | 299 | 47 | 849 | |
Cash Fr. Inv. | -109 | -115 | -176 | -299 | -1,116 | -612 | -167 | -103 | -5 | -477 | |
Cash Fr. Finan. | -35 | 29 | 154 | -48 | 651 | -51 | -251 | -186 | 35 | -363 | |
Net Change | 0 | 7 | 91 | -1 | -1 | 6 | -1 | 10 | 76 | 9 | |
Cash & Cash Eqvt | 10 | 12 | -74 | 24 | 22 | 28 | 20 | 26 | 111 | 132 |
Thu, 18 Apr 2024
Updates Natco Pharma Limited has informed the Exchange regarding 'Updates'. |
Thu, 18 Apr 2024
Analysts/Institutional Investor Meet/Con. Call Updates Natco Pharma Limited has informed the Exchange about Schedule of meet |
Fri, 12 Apr 2024
Disclosure under SEBI Takeover Regulations Natco Pharma Limitedᅡᅠhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indiaᅡᅠ(Substantial Acquisition of Shares and Takeovers) Regulations, 2011 |
Thu, 18 Apr 2024 |
Close Within 52 Week High Zone |
Making Higher Highs for 2 Days |
High Increase in 3 Months |
High Increase in 1 Year |
William %R Trending Up |